Literature DB >> 19524579

Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

Anna Kotronen1, Markku Peltonen, Antti Hakkarainen, Ksenia Sevastianova, Robert Bergholm, Lina M Johansson, Nina Lundbom, Aila Rissanen, Martin Ridderstråle, Leif Groop, Marju Orho-Melander, Hannele Yki-Järvinen.   

Abstract

BACKGROUND & AIMS: Our aims were to develop a method to accurately predict non-alcoholic fatty liver disease (NAFLD) and liver fat content based on routinely available clinical and laboratory data and to test whether knowledge of the recently discovered genetic variant in the PNPLA3 gene (rs738409) increases accuracy of the prediction.
METHODS: Liver fat content was measured using proton magnetic resonance spectroscopy in 470 subjects, who were randomly divided into estimation (two thirds of the subjects, n = 313) and validation (one third of the subjects, n = 157) groups. Multivariate logistic and linear regression analyses were used to create an NAFLD liver fat score to diagnose NAFLD and liver fat equation to estimate liver fat percentage in each individual.
RESULTS: The presence of the metabolic syndrome and type 2 diabetes, fasting serum (fS) insulin, fS-aspartate aminotransferase (AST), and the AST/alanine aminotransferase ratio were independent predictors of NAFLD. The score had an area under the receiver operating characteristic curve of 0.87 in the estimation and 0.86 in the validation group. The optimal cut-off point of -0.640 predicted increased liver fat content with sensitivity of 86% and specificity of 71%. Addition of the genetic information to the score improved the accuracy of the prediction by only <1%. Using the same variables, we developed a liver fat equation from which liver fat percentage of each individual could be estimated.
CONCLUSIONS: The NAFLD liver fat score and liver fat equation provide simple and noninvasive tools to predict NAFLD and liver fat content.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524579     DOI: 10.1053/j.gastro.2009.06.005

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  220 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 3.  Genome-wide association studies and genetic risk assessment of liver diseases.

Authors:  Marcin Krawczyk; Roman Müllenbach; Susanne N Weber; Vincent Zimmer; Frank Lammert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

4.  A prospective study of artificially sweetened beverage intake and cardiometabolic health among women at high risk.

Authors:  Stefanie N Hinkle; Shristi Rawal; Anne Ahrendt Bjerregaard; Thor I Halldorsson; Mengying Li; Sylvia H Ley; Jing Wu; Yeyi Zhu; Liwei Chen; Aiyi Liu; Louise Groth Grunnet; Mohammad L Rahman; Freja Bach Kampmann; James L Mills; Sjurdur F Olsen; Cuilin Zhang
Journal:  Am J Clin Nutr       Date:  2019-07-01       Impact factor: 7.045

Review 5.  Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Authors:  Chiara Saponaro; Melania Gaggini; Amalia Gastaldelli
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

Review 6.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

7.  Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.

Authors:  N S Patel; M R Peterson; D A Brenner; E Heba; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

8.  Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.

Authors:  Vanessa El Kamari; Corrilynn O Hileman; Pierre M Gholam; Manjusha Kulkarni; Nicholas Funderburg; Grace A McComsey
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

9.  Associations between dietary factors and markers of NAFLD in a general Dutch adult population.

Authors:  A Rietman; D Sluik; E J M Feskens; F J Kok; M Mensink
Journal:  Eur J Clin Nutr       Date:  2017-09-13       Impact factor: 4.016

10.  Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study.

Authors:  Beverley Balkau; Celine Lange; Sylviane Vol; Frederic Fumeron; Fabrice Bonnet
Journal:  BMC Gastroenterol       Date:  2010-06-07       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.